

7th Global Conference on **CELL AND GENE THERAPY**

July 15-16, 2024 | London, UK

Transfusion/cell/therapeutic products transmitted disorders issue in bone marrow transplanted patients, (and other cell therapeutic modalities)**Miklos Udvardy***University of Debrecen, Hungary*

Transfusion medicine is traditionally strong/fundamental part of clinical practice. However, blood borne or transmitted infections are well-known and feared possibility, a risk we relentlessly mitigate. Pathogens are continuously and rather quickly changing, so during the last decade, many, sometimes exotic new pathogens and diseases were recorded and analyzed, and some of them, like Zika or monkey pox viruses, were proved to be transmitted with transfusions and many pathogens became epidemic in unexpected geographical regions (Dengue, NSV. etc.). Blood or blood component transfusions are carried out after cautious preparative screening and inactivation maneuvers, but in some instances, newly recognized agents might escape from standard screening and inactivation procedures. Here we focus on some of these proven or potentially pathogenic transfusion-transmitted agents, especially bone marrow transplantation settings along with the potential transmission hazards in other kinds of allogeneous clinical cell therapies. This time we will review new data of really unexpected infections like rabies, leptospirosis, brucella which might go through cell harvesting screens and procedures with really dangerous consequences. Especially exciting topic is the personalized platelet substitution issue, normal platelet transfusion is more infective compared to red blood cell transfusion, otherwise cooling modifies the properties of platelet transfusions, we have to consider infection risk, which temperature is more hemostatic, or more suitable for attaining safe platelet counts. These are new challenges for preparative procedures, and there is a need for more recent, occasionally advanced screening and inactivation methods even more in cell therapies of frequently immunocompromised and highly endangered patients.

Biography

Miklos Udvardy is a prominent researcher at the University of Debrecen in Hungary, focusing on hematology and transplantation medicine. His research primarily investigates the transmission of disorders through transfusions and cellular therapeutic products in bone marrow transplant patients and other cell-based therapies. Miklos aims to improve patient safety and outcomes, contributing to the advancement of cell therapy.